Haleon plc (NYSE:HLN) Shares Sold by US Bancorp DE

US Bancorp DE lessened its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 6.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 757,469 shares of the company's stock after selling 55,207 shares during the period. US Bancorp DE's holdings in Haleon were worth $8,014,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Janney Montgomery Scott LLC increased its position in Haleon by 182.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company's stock worth $3,726,000 after purchasing an additional 283,410 shares in the last quarter. Manning & Napier Advisors LLC purchased a new stake in Haleon during the second quarter valued at about $2,833,000. First Eagle Investment Management LLC increased its position in Haleon by 31.0% during the 1st quarter. First Eagle Investment Management LLC now owns 1,361,021 shares of the company's stock worth $11,555,000 after purchasing an additional 321,928 shares in the last quarter. Orion Portfolio Solutions LLC raised its stake in shares of Haleon by 25.1% in the 1st quarter. Orion Portfolio Solutions LLC now owns 694,524 shares of the company's stock valued at $5,897,000 after acquiring an additional 139,263 shares during the period. Finally, Sei Investments Co. raised its position in Haleon by 79.1% in the first quarter. Sei Investments Co. now owns 781,089 shares of the company's stock valued at $6,632,000 after purchasing an additional 345,036 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Up 0.3 %

Shares of HLN stock traded up $0.03 during trading hours on Monday, hitting $9.76. 4,533,209 shares of the company were exchanged, compared to its average volume of 5,187,076. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $44.18 billion, a price-to-earnings ratio of 28.85, a P/E/G ratio of 2.83 and a beta of 0.30. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The business's 50-day simple moving average is $10.23 and its two-hundred day simple moving average is $9.27.

Haleon (NYSE:HLN - Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The firm had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. During the same quarter in the previous year, the business posted $0.08 EPS. Sell-side analysts predict that Haleon plc will post 0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HLN. Morgan Stanley lifted their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research note on Friday, September 20th. Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a "buy" rating on the stock. The Goldman Sachs Group downgraded Haleon from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 6th. Finally, UBS Group raised Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.